Supernus Pharmaceuticals Gross Margin 2011-2024 | SUPN

Current and historical gross margin for Supernus Pharmaceuticals (SUPN) over the last 10 years. The current gross profit margin for Supernus Pharmaceuticals as of September 30, 2024 is %.
Supernus Pharmaceuticals Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2024-09-30 $0.65B $0.58B 88.96%
2024-06-30 $0.63B $0.56B 88.25%
2024-03-31 $0.60B $0.52B 86.96%
2023-12-31 $0.61B $0.52B 86.02%
2023-09-30 $0.61B $0.52B 85.43%
2023-06-30 $0.63B $0.54B 85.02%
2023-03-31 $0.67B $0.58B 86.08%
2022-12-31 $0.67B $0.58B 86.96%
2022-09-30 $0.66B $0.58B 87.71%
2022-06-30 $0.63B $0.56B 88.41%
2022-03-31 $0.60B $0.52B 87.02%
2021-12-31 $0.58B $0.50B 87.05%
2021-09-30 $0.56B $0.49B 86.35%
2021-06-30 $0.57B $0.49B 85.99%
2021-03-31 $0.56B $0.49B 88.51%
2020-12-31 $0.52B $0.47B 89.83%
2020-09-30 $0.48B $0.44B 92.03%
2020-06-30 $0.42B $0.40B 94.81%
2020-03-31 $0.40B $0.39B 95.77%
2019-12-31 $0.39B $0.38B 95.92%
2019-09-30 $0.41B $0.39B 96.08%
2019-06-30 $0.41B $0.39B 96.33%
2019-03-31 $0.40B $0.39B 96.29%
2018-12-31 $0.41B $0.39B 96.33%
2018-09-30 $0.38B $0.37B 96.06%
2018-06-30 $0.36B $0.34B 95.81%
2018-03-31 $0.33B $0.32B 95.51%
2017-12-31 $0.30B $0.29B 95.03%
2017-09-30 $0.28B $0.26B 94.93%
2017-06-30 $0.25B $0.24B 94.47%
2017-03-31 $0.23B $0.22B 94.32%
2016-12-31 $0.22B $0.20B 94.42%
2016-09-30 $0.20B $0.19B 93.91%
2016-06-30 $0.18B $0.17B 94.41%
2016-03-31 $0.16B $0.15B 94.48%
2015-12-31 $0.15B $0.14B 93.92%
2015-09-30 $0.14B $0.13B 94.07%
2015-06-30 $0.12B $0.11B 93.28%
2015-03-31 $0.11B $0.11B 92.92%
2014-12-31 $0.09B $0.09B 93.55%
2014-09-30 $0.07B $0.07B 93.06%
2014-06-30 $0.05B $0.05B 94.00%
2014-03-31 $0.02B $0.02B 95.00%
2013-12-31 $0.01B $0.01B 90.91%
2013-09-30 $0.00B $0.00B 100.00%
2013-06-30 $0.00B $0.00B 100.00%
2013-03-31 $0.00B $0.00B 100.00%
2012-12-31 $0.00B $0.00B 100.00%
2012-09-30 $0.00B 0 nan%
2012-06-30 $0.00B 0 nan%
2012-03-31 $0.00B $0.00B 100.00%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.962B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00